NBIX

159.76

1.81% -2.95

Dopo l'orario di chiusura: 159.76

Neurocrine Biosciences Inc (NBIX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Storia dei dividendi

Precedente Chiudi:

$162.71

Aprire:

$162.04

Volume 24 ore:

1.06M

Relative Volume:

0.91

Capitalizzazione di mercato:

$16.06B

Reddito:

$3.10B

Utile/perdita netta:

$668.60M

Rapporto P/E:

24.56

EPS:

6.5044

Flusso di cassa netto:

$831.30M

1 W Prestazione:

-2.51%

1M Prestazione:

+2.54%

6M Prestazione:

+4.55%

1 anno Prestazione:

+27.80%

Intervallo 1D:

$159.44

$162.97

Intervallo di 1 settimana:

$159.44

$169.39

Portata 52W:

$122.14

$169.57

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Nome

Neurocrine Biosciences Inc

Settore

Healthcare (1109)

Industria

Drug Manufacturers - Specialty & Generic (88)

Telefono

(858) 617-7600

Indirizzo

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Dipendente

2,000

Cinguettio

Prossima data di guadagno

2026-07-29

Ultimi documenti SEC

NBIX's Discussions on Twitter

Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NBIX Neurocrine Biosciences Inc	159.76	16.06B	3.10B	668.60M	831.30M	6.5044
TAK Takeda Pharmaceutical Co Adr	15.91	50.27B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	34.63	40.32B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.13	40.31B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.57	33.36B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	545.96	23.17B	3.17B	1.29B	1.01B	27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-24	Iniziato	Wolfe Research	Outperform
2026-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-10-21	Iniziato	Citigroup	Buy
2025-07-21	Iniziato	Truist	Buy
2025-07-10	Iniziato	Goldman	Buy
2025-04-15	Aggiornamento	Needham	Hold → Buy
2025-04-14	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2025-02-11	Iniziato	Deutsche Bank	Hold
2024-10-10	Ripresa	Raymond James	Outperform
2024-08-29	Aggiornamento	Piper Sandler	Neutral → Overweight
2024-04-24	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-12-13	Ripresa	Citigroup	Neutral
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-10-24	Ripresa	Cantor Fitzgerald	Overweight
2023-08-21	Reiterato	Mizuho	Neutral
2023-07-24	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-07-06	Aggiornamento	BMO Capital Markets	Underperform → Market Perform
2023-05-04	Aggiornamento	Guggenheim	Neutral → Buy
2023-03-30	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-03-03	Aggiornamento	Evercore ISI	In-line → Outperform
2023-02-03	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-11-14	Downgrade	Evercore ISI	Outperform → In-line
2022-10-11	Iniziato	UBS	Buy
2022-09-26	Iniziato	Wells Fargo	Equal Weight
2022-06-06	Ripresa	Jefferies	Buy
2022-03-03	Downgrade	Piper Sandler	Overweight → Neutral
2022-02-25	Aggiornamento	Goldman	Neutral → Buy
2022-01-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2021-11-19	Iniziato	BMO Capital Markets	Underperform
2021-11-17	Aggiornamento	JP Morgan	Neutral → Overweight
2021-10-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Ripresa	Needham	Hold
2021-08-06	Downgrade	Canaccord Genuity	Buy → Hold
2021-05-18	Ripresa	Goldman	Neutral
2021-05-06	Aggiornamento	Barclays	Equal Weight → Overweight
2021-02-02	Iniziato	Raymond James	Outperform
2020-09-30	Iniziato	The Benchmark Company	Hold
2020-08-04	Downgrade	JP Morgan	Overweight → Neutral
2020-06-29	Downgrade	Goldman	Buy → Neutral
2020-06-09	Iniziato	Wedbush	Outperform
2020-03-06	Iniziato	Citigroup	Buy
2020-02-27	Iniziato	Barclays	Equal Weight
2020-02-24	Iniziato	William Blair	Outperform
2020-02-06	Iniziato	Mizuho	Neutral
2020-02-05	Reiterato	H.C. Wainwright	Buy
2019-12-13	Downgrade	Credit Suisse	Outperform → Neutral
2019-08-07	Iniziato	RBC Capital Mkts	Outperform
2019-07-16	Iniziato	Oppenheimer	Outperform
2019-06-05	Iniziato	Guggenheim	Neutral
2019-05-21	Iniziato	Credit Suisse	Outperform
2019-04-22	Aggiornamento	JP Morgan	Neutral → Overweight
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-02-06	Reiterato	BofA/Merrill	Buy
2019-01-23	Downgrade	JP Morgan	Overweight → Neutral
2018-12-13	Iniziato	Goldman	Buy
2018-11-21	Iniziato	Canaccord Genuity	Buy

Mostra tutto

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

Jun 12, 2026

Marquis Who's Who Honors Noah Post for Expertise in Pharmaceuticals - 24-7 Press Release Newswire

Jun 12, 2026

Jun 11, 2026

Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - simplywall.st

Jun 11, 2026

Neurocrine Biosciences (NBIX) beats Q1 earnings and revenue estimates - MSN

Jun 11, 2026

Jun 10, 2026

INGREZZA Data In Complex Patients Adds Support For Neurocrine Valuation Story - simplywall.st

Jun 10, 2026

Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys - Benzinga

Jun 10, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book Strategy - ChartMill

Jun 10, 2026

Jun 09, 2026

Neurocrine Biosciences(NBIX.US) Director Sells US$4.13 Million in Common Stock - Moomoo

Jun 09, 2026

Neurocrine Biosciences director Stephen A. Sherwin sells $4.13m stock - Investing.com UK

Jun 09, 2026

Neurocrine Biosciences director Stephen A. Sherwin sells $4.13m stock By Investing.com - Investing.com Canada

Jun 09, 2026

Neurocrine (NBIX) director exercises 25K options and sells 25K shares under 10b5-1 plan - Stock Titan

Jun 09, 2026

[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan

Jun 09, 2026

Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 09 - marketscreener.com

Jun 09, 2026

Jun 08, 2026

Cerebral Palsy Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - Barchart.com

Jun 08, 2026

Neurocrine presents tardive dyskinesia treatment data at conference - StreetInsider

Jun 08, 2026

Neurocrine Biosciences director sells $210,071 in stock By Investing.com - Investing.com South Africa

Jun 08, 2026

Neurocrine Biosciences director sells $210,071 in stock - Investing.com

Jun 08, 2026

Neurocrine (NBIX) director sells 1,250 shares under Rule 10b5-1 plan - Stock Titan

Jun 08, 2026

Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients - PR Newswire

Jun 08, 2026

Neurocrine reports positive INGREZZA data for TD in patients with IDD - grafa.com

Jun 08, 2026

Neurocrine presents data on tardive dyskinesia treatment - Investing.com

Jun 08, 2026

Neurocrine presents data on tardive dyskinesia treatment By Investing.com - Investing.com Australia

Jun 08, 2026

Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities - PR Newswire

Jun 08, 2026

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score - ChartMill

Jun 08, 2026

Jun 06, 2026

Neurocrine publishes dosing guidelines for CAH treatment drug - Investing.com

Jun 06, 2026

Jun 05, 2026